肝癖(非酒精性脂肪性肝炎)诊疗方案

Diagnosis and treatment scheme of Ganpi(non-alcoholic steatohepatitis)

随着生活水平的提高,中国脂肪性肝病(简称脂肪肝)的发病率逐年提高,已成为我国第一大肝病。脂肪肝的危害正在逐步被医学界重视,但目前尚缺乏有效的药物治疗,中医药在脂肪肝方面的优势已得到广大医生和患者的认可。为进一步提高脂肪肝的中医药疗效,深圳市中医院肝病科依托国家中医药管理局华南区中医肝病诊疗中心联盟理事长单位,牵头联合广东省、广西壮族自治区和海南省肝病专家,以国家中医药管理局发布的《肝癖(脂肪性肝病)诊疗方案》为蓝本,结合脂肪肝的研究进展,更新、修订形成了《肝癖(非酒精性脂肪性肝炎)诊疗方案》,为华南区肝癖的中医预防、辨证治疗提供依据。

The incidence of fatty liver disease has been increasing and developed into the first major liver disease in China.The risks of fatty liver disease has been gradually paid attention to by the medical,however,there is still lack of effective medicines,so the advantages of traditional Chinese medicine for fatty liver disease have been recognized.In order to furtherly improve the effect of traditional Chinese medicine on fatty liver disease,as the director of Diagnosis and Treatment Center of Hepatology of South China Alliance of TCM,National Administration of Traditional Chinese Medicine,the hepatology department of Shenzhen Traditional Chinese Medicine Hospital cooperated with the experts on liver diseases from Guangdong,Guangxi Zhuang Autonomous Region and Hainan province and formed“diagnosis and treatment scheme of Ganpi(nonalcoholic steatohepatitis)”,which is based on the progress of fatty liver disease and“diagnosis and treatment scheme of Ganpi(fatty liver disease)”issued by the National Administration of Traditional Chinese Medicine.The aim of this new“diagnosis and treatment scheme of Ganpi(non-alcoholic steatohepatitis)”is to provide basis for diagnosis and treatment of traditional Chinese medicine on Ganpi in south China.